UBE2S在消化系统肿瘤中的研究进展
Research Progress of UBE2S in Digestive Sys-tem Tumors
DOI: 10.12677/ACM.2023.13112476, PDF,    国家自然科学基金支持
作者: 李 湾, 马遇庆*：新疆医科大学第一附属医院病理科，新疆 乌鲁木齐
关键词: 消化系统肿瘤；UBE2S；肿瘤标志物；诊断；预后；Digestive System Tumor； UBE2S； Tumor Markers； Diagnosis； Prognosis
摘要: 泛素结合酶2S (UBE2S)作为泛素结合酶(E2)家族成员之一，是一种细胞周期调控的泛素结合酶，在消化系统肿瘤中特异性表达，且表达水平明显高于癌旁组织，同时UBE2S高表达患者预后较差。研究表明UBE2S在口腔鳞癌、食管癌、胃癌、肝细胞癌、胆囊癌和胰腺癌等消化系统肿瘤中发挥促癌的作用，因此UBE2S可能成为消化系统肿瘤早期诊断及预后预测的标志物。本文就UBE2S的结构和功能及其与消化系统肿瘤的研究进展作一综述，为诊治消化系统肿瘤提供理论依据。
Abstract: Ubiquitin-conjugating enzyme 2S (UBE2S), as a member of Ubiquitin-conjugating enzyme (E2) fam-ily, is an ubiquitin ligase regulated by cell cycle. It is specifically expressed in digestive system tu-mors, and its expression level is significantly higher than that in adjacent tissues. At the same time, patients with high UBE2S expression have poor prognosis. Studies have shown that UBE2S plays a promoting role in digestive system tumors such as oral squamous cell carcinoma, esophageal carci-noma, gastric cancer, liver cancer, gallbladder cancer and pancreatic cancer, so UBE2S may become a marker for early diagnosis and prognosis prediction of digestive system tumors. In this paper, the structure and function of UBE2S and its research progress in digestive system tumors are reviewed, so as to provide theoretical basis for diagnosis and treatment of digestive system tumors.
文章引用：李湾, 马遇庆. UBE2S在消化系统肿瘤中的研究进展[J]. 临床医学进展, 2023, 13(11): 17659-17664. https://doi.org/10.12677/ACM.2023.13112476

参考文献

[1] Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. [Google Scholar] [CrossRef] [PubMed]
[2] Ning, S., Wei, W., Li, J., et al. (2018) Clinical Significance and Diagnostic Capacity of Serum TK1, CEA, CA 19-9 and CA 72-4 Levels in Gastric and Colorectal Cancer Patients. Journal of Cancer, 9, 494-501. [Google Scholar] [CrossRef] [PubMed]
[3] Wu, T., Merbl, Y., Huo, Y., et al. (2010) UBE2S Drives Elongation of K11-Linked Ubiquitin Chains by the Anaphase-Promoting Complex. Proceedings of the National Academy of Sciences of the United States of America, 107, 1355-1360. [Google Scholar] [CrossRef] [PubMed]
[4] Garnett, M.J., Mansfeld, J., Godwin, C., et al. (2009) UBE2S Elongates Ubiquitin Chains on APC/C Substrates to Promote Mitotic Exit. Nature Cell Biology, 11, 1363-1369. [Google Scholar] [CrossRef] [PubMed]
[5] Paul, A. and Wang, B. (2017) RNF8- and Ube2S-Dependent Ubiquitin Lysine 11-Linkage Modification in Response to DNA Damage. Molecular Cell, 66, 458-472.e455. [Google Scholar] [CrossRef] [PubMed]
[6] Li, Z., Wang, Y., Li, Y., et al. (2018) Ube2s Stabilizes β-Catenin through K11-Linked Polyubiquitination to Promote Mesendoderm Specification and Colorectal Can-cer Development. Cell Death & Disease, 9, Article No. 456. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, L., Liang, Y., Li, P., et al. (2019) Oncogenic Activities of UBE2S Mediated by VHL/HIF-1α/STAT3 Signal via the Ubiquitin-Proteasome System in PDAC. OncoTargets and Therapy, 12, 9767-9781. [Google Scholar] [CrossRef] 
[8] Liang, J., Nishi, H., Bian, M.L., et al. (2012) The Ubiqui-tin-Conjugating Enzyme E2-EPF Is Overexpressed in Cervical Cancer and Associates with Tumor Growth. Oncology Reports, 28, 1519-1525. [Google Scholar] [CrossRef] [PubMed]
[9] Li, X., Elmira, E., Rohondia, S., et al. (2018) A Patent Review of the Ubiquitin Ligase System: 2015-2018. Expert Opinion on Therapeutic Patents, 28, 919-937. [Google Scholar] [CrossRef] [PubMed]
[10] Sheng, Y., Hong, J.H., Doherty, R., et al. (2012) A Human Ubiquitin Conjugating Enzyme (E2)-HECT E3 Ligase Structure-Function Screen. Molecular & Cellular Proteomics: MCP, 11, 329-341. [Google Scholar] [CrossRef] 
[11] Chang, L., Zhang, Z., Yang, J., et al. (2015) Atomic Structure of the APC/C and Its Mechanism of Protein Ubiquitination. Nature, 522, 450-454. [Google Scholar] [CrossRef] [PubMed]
[12] Torre, L.A., Bray, F., Siegel, R.L., et al. (2015) Global Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians, 65, 87-108. [Google Scholar] [CrossRef] [PubMed]
[13] Gao, W. and Guo, C.B. (2009) Factors Related to Delay in Diagnosis of Oral Squamous Cell Carcinoma. Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons, 67, 1015-1020. [Google Scholar] [CrossRef] [PubMed]
[14] Yoshimura, S., Kasamatsu, A., Nakashima, D., et al. (2017) UBE2S Associated with OSCC Proliferation by Promotion of P21 Degradation via the Ubiquitin-Proteasome System. Biochemical and Biophysical Research Communications, 485, 820-825. [Google Scholar] [CrossRef] [PubMed]
[15] Cao, W., Chen, H.D., Yu, Y.W., et al. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal (England), 134, 783-791. [Google Scholar] [CrossRef] 
[16] 毛友生, 高树庚, 王群, 等. 中国食管癌临床流行特征及外科治疗概况大数据分析[J]. 中华肿瘤杂志, 2020, 42(3): 228-233.
[17] Chen, M.F., Lee, K.D., Lu, M.S., et al. (2009) The Predictive Role of E2-EPF Ubiquitin Carrier Protein in Esophageal Squamous Cell Carcinoma. Journal of Molecular Medicine (Berlin), 87, 307-320. [Google Scholar] [CrossRef] [PubMed]
[18] Ajani, J.A., Bentrem, D.J., Besh, S., et al. (2013) Gastric Cancer, Version 2.2013: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 11, 531-546.
[19] Zhao, R., Yu, Z., Mao, X., et al. (2022) Knockout of UBE2S Inhibits the Proliferation of Gastric Cancer Cells and Induces Apoptosis by FAS-Mediated Death Receptor Pathway. Experimental Cell Research, 419, Article ID: 113293. [Google Scholar] [CrossRef] [PubMed]
[20] Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Can-cer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[21] Forner, A., Reig, M. and Bruix, J. (2018) Hepatocellular Carcinoma. The Lancet (London, England), 391, 1301-1314. [Google Scholar] [CrossRef] 
[22] Tralhão, J.G., Dagher, I., Lino, T., et al. (2007) Treatment of Tumour Recurrence after Resection of Hepatocellular Carcinoma. Analysis of 97 Consecutive Patients. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 33, 746-751. [Google Scholar] [CrossRef] [PubMed]
[23] Poon, R.T. (2011) Prevention of Recurrence after Resection of Hepatocellular Carcinoma: A Daunting Challenge. Hepatology (Baltimore, Md), 54, 757-759. [Google Scholar] [CrossRef] [PubMed]
[24] Yen, Y., Lim, D.W., Chung, V., et al. (2008) Phase II Study of Oxaliplatin in Patients with Unresectable, Metastatic, or Recurrent Hepatocellular Cancer: A California Cancer Consortium Trial. American Journal of Clinical Oncology, 31, 317-322. [Google Scholar] [CrossRef] 
[25] Ma, S., Lee, T.K., Zheng, B.J., et al. (2008) CD133+ HCC Cancer Stem Cells Confer Chemoresistance by Preferential Expres-sion of the Akt/PKB Survival Pathway. Oncogene, 27, 1749-1758. [Google Scholar] [CrossRef] [PubMed]
[26] Gui, L., Zhang, S., Xu, Y., et al. (2021) UBE2S Promotes Cell Chemoresistance through PTEN-AKT Signaling in Hepatocellular Carcinoma. Cell Death Discovery, 7, Article No. 357. [Google Scholar] [CrossRef] [PubMed]
[27] Li, Q., Zhao, Y., Shi, X., et al. (2018) Ube2s Expression Is Ele-vated in Hepatocellular Carcinoma and Predicts Poor Prognosis of the Patients. International Journal of Clinical and Ex-perimental Pathology, 11, 781-787.
[28] Pan, Y.H., Yang, M., Liu, L.P., et al. (2018) UBE2S Enhances the Ubiquitina-tion of p53 and Exerts Oncogenic Activities in Hepatocellular Carcinoma. Biochemical and Biophysical Research Com-munications, 503, 895-902. [Google Scholar] [CrossRef] [PubMed]
[29] Lim, J.H., Kim, D.G., Yu, D.Y., et al. (2019) Stabilization of E2-EPF UCP Protein Is Implicated in Hepatitis B Virus-Associated Hepatocellular Carcinoma Progression. Cellular and Molecular Life Sciences: CMLS, 76, 2647-2662. [Google Scholar] [CrossRef] [PubMed]
[30] Hundal, R. and Shaffer, E.A. (2014) Gallbladder Cancer: Epide-miology and Outcome. Clinical Epidemiology, 6, 99-109. [Google Scholar] [CrossRef] 
[31] Sharma, A., Sharma, K.L., Gupta, A., et al. (2017) Gallbladder Cancer Epidemiology, Pathogenesis and Molecular Genetics: Recent Update. World Journal of Gastroenterology, 23, 3978-3998. [Google Scholar] [CrossRef] [PubMed]
[32] Roa, J.C., García, P., Kapoor, V.K., et al. (2022) Gallbladder Cancer. Nature Reviews Disease Primers, 8, Article No. 69. [Google Scholar] [CrossRef] [PubMed]
[33] 曹进, 张景涛, 刘中砚, 等. 泛素结合酶E2s在胆囊癌患者中的高表达及意义[J]. 中华实验外科杂志, 2018, 35(7): 1321-1324.
[34] Whittle, M.C., Izeradjene, K., Rani, P.G., et al. (2015) RUNX3 Controls a Metastatic Switch in Pan-creatic Ductal Adenocarcinoma. Cell, 161, 1345-1360. [Google Scholar] [CrossRef] [PubMed]

为你推荐